XML 47 R38.htm IDEA: XBRL DOCUMENT v3.22.1
License and Collaboration Agreements - Narrative (Details)
1 Months Ended 3 Months Ended 87 Months Ended
May 28, 2021
USD ($)
Aug. 03, 2020
USD ($)
shares
Jan. 07, 2018
USD ($)
Oct. 31, 2014
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Oct. 01, 2014
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Expenses related to collaboration agreement         $ 130,976,000   $ 104,071,000    
Milestone Payments                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Expenses related to collaboration agreement         0   0    
BeiGene Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Termination of contract, period after first commercial sale of product     10 years            
Period required for notice of termination of contract     60 days            
Performance obligation, compensation to be earned     $ 500,000            
Royalty revenue         0   0    
Research and Development Arrangement, Up-Front Fee Received     10,000,000            
Research and Development Arrangement, Contract to Perform for Others, Compensation Expected to be Earned     $ 123,000,000            
BeiGene Agreement | Maximum                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Royalty percentage rate (up to)     0.20            
BeiGene Agreement | Licenses of Intellectual Property                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Performance obligation, compensation to be earned     $ 9,500,000            
Milestone payments earned         0   0    
BeiGene Agreement | Manufacturing Supply Services                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognized         0   $ 0    
Pfizer Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Termination of contract, period after first commercial sale of product       10 years          
Period required for notice of termination of contract       60 days          
Pfizer Agreement | Development Milestone Payments                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and Development Arrangement, Discovery and Collaboration Agreement, Compensation Expected to be Paid                 $ 9,300,000
Research and Development Arrangement, Discovery and Collaboration Agreement, Milestone Payments Paid               $ 9,500,000  
Pfizer Agreement | Sales Milestone Payments                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Research and Development Arrangement, Discovery and Collaboration Agreement, Compensation Expected to be Paid                 $ 337,000,000
ORIC Pharmaceuticals Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Stock received as part of stock issuance and license agreements (shares) | shares   588,235              
License agreement, period of transfer restrictions   18 months              
License agreement, period of agreement after first commercial sale   10 years              
ORIC Pharmaceuticals Agreement | Level 3                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
License Agreement, One-Time Non-Cash Payment   $ 11,400,000              
Zai Agreement                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Up-front fee received $ 65,000,000                
Period required for notice of termination of contract 12 months                
Transaction price of arrangement $ 66,600,000                
Milestone payments earned         0        
Termination of contract, period after first commercial sale of product 10 years                
Zai Agreement | Licenses of Intellectual Property                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognized           $ 66,600,000      
Unrealized loss on available-for-sale investments           $ 3,300,000      
Zai Agreement | Manufacturing Supply Services                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue recognized         700,000        
Zai Agreement | Sales Milestone Payments                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue from performance obligation expected to be earned $ 180,000,000                
Zai Agreement | Development and Regulatory Milestone Payments                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue from performance obligation expected to be earned $ 93,000,000                
Zai Agreement | Royalties                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Royalty revenue         $ 0